Hyphens Pharma International debuts in Catalist board

Its IPO was 152 times subscribed and raised $13.5m.

Hyphens Pharma International Limited joined the Singapore Exchange (SGX) Catalist under the stock code 1J5. It opened at 30 cents on May 18.

After its initial public offering (IPO), the company was able to raise $13.5m. Its public offer was 152 times subscribed.

Hyphens Pharma International chairman, executive director, and CEO Lim See Wah commented, "With the success of our IPO, we are well-placed to expand and strengthen our product range and maintain growth momentum through scaling our presence in markets that we operate in and expanding into new geographical markets. We are delighted to have our stakeholders participate alongside our growth story.”

Hyphens Pharma International a Singapore-based speciality pharmaceutical and consumer healthcare group with a footprint in ASEAN countries.

It sells and markets speciality pharmaceutical products for brand principals mainly from Europe and the United States. It also has its own dermatological products and health supplement products through Hyphens and Ocean Health Singapore.

With a market capitalisation of $78m, the listing of Hyphens Pharma International Limited brings the total number of healthcare companies listed on SGX to 38, with a combined market capitalisation of more than $63b.

The total number of companies listed on Catalist is now up to 205, with a combined market capitalisation of over $12b.